PDF(Pubmed)
Abstract：
Lung cancer continues to be the third leading cause of cancer and the leading cause of cancer deaths. As the field of interventional oncology continues to grow, interventional radiologists are increasingly treating lung cancer patients. Involvement begins with tissue diagnosis for which biomarkers and immunohistochemistry are used to guide selective and advanced medical therapies. An interventional radiologist must be aware of the rationale behind tissue diagnosis and techniques to minimize biopsy complications. Staging is an important part of tumor board conversations and drives treatment pathways. Surgical therapy remains the gold standard for early-stage disease but with an aging population the need for less invasive treatments such as radiation therapy and ablation continue to grow. The interventionalist must be aware of the indications, techniques, and pre- and posttherapy managements for percutaneous ablation. Endovascular therapy is broadly divided into therapeutic treatment of lung cancer, which is gaining traction, and treatment of lung cancer complications such as hemoptysis. This review aims to provide a good basis for interventional radiologists treating lung cancer patients.
摘要：
肺癌仍然是癌症的第三大原因和癌症死亡的主要原因。随着介入肿瘤学领域的不断发展，介入放射科医生越来越多地治疗肺癌患者。参与始于组织诊断，生物标志物和免疫组织化学用于指导选择性和先进的医学治疗。介入放射科医生必须了解组织诊断和技术背后的基本原理，以最大程度地减少活检并发症。分期是肿瘤委员会对话的重要组成部分，并推动治疗途径。手术治疗仍然是早期疾病的黄金标准，但随着人口老龄化，对侵入性较小的治疗如放射治疗和消融的需求持续增长。干预主义者必须意识到这些迹象，技术,以及经皮消融的治疗前后管理。血管内治疗大致分为肺癌的治疗性治疗,正在获得牵引力，以及治疗肺癌咯血等并发症。本文旨在为介入放射科医生治疗肺癌患者提供良好的依据。
